Tosin Oshionebo
Family · Dallas, TXNPI 1538529797
Payments from drug & device makers
Across 469 payments — averaging $17.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$1K
- Grifols USA, LLC$850
- Mallinckrodt Hospital Products Inc.$582
- Boehringer Ingelheim$568
- Takeda Pharmaceuticals U.S.A., Inc.$521
- plus $3K from 33 others
What the payments were for
- Food & beverage$7,78196%
- Education$3204%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 57 | $1,350 |
| GSK | 71 | $1,056 |
| Grifols USA, LLC | 54 | $850 |
| Mallinckrodt Hospital Products Inc. | 35 | $582 |
| Boehringer Ingelheim | 33 | $568 |
| Takeda Pharmaceuticals U.S.A., Inc. | 38 | $521 |
| Actelion Pharmaceuticals US, Inc. | 16 | $424 |
| Regeneron Healthcare Solutions, Inc. | 14 | $258 |
| United Therapeutics Corporation | 14 | $242 |
| Electromed, Inc. | 16 | $219 |
| ANI Pharmaceuticals, Inc. | 13 | $203 |
| Baxter Healthcare | 17 | $199 |
| Amgen | 8 | $154 |
| Sanofi | 13 | $153 |
| Advanced Respiratory, Inc | 16 | $126 |
| Mylan Specialty L.p. | 6 | $114 |
| Kyowa Kirin, Inc. | 1 | $110 |
| Harmony Biosciences LLC | 5 | $110 |
| Sanofi-aventis U.S. LLC | 1 | $90 |
| Insmed, Inc. | 5 | $89 |
| Merck | 5 | $88 |
| Philips North America LLC | 4 | $81 |
| Verona Pharma, Inc. | 4 | $79 |
| Pfizer | 3 | $71 |
| Viatris Specialty LLC | 3 | $62 |
| Teva Pharmaceuticals USA, Inc. | 2 | $43 |
| Boston Scientific | 2 | $34 |
| Tactile Systems Technology Inc | 2 | $32 |
| Vifor Pharma, Inc. | 1 | $23 |
| Optinose US, Inc. | 1 | $20 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $19 |
| Pulmonx Corporation | 1 | $19 |
| Phadia US Inc. | 1 | $17 |
| 3b Medical, Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $17 |
| Bayer | 1 | $16 |
| Eisai Inc. | 1 | $15 |
| Inogen, Inc. | 1 | $15 |
| Paratek Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UPTRAVI$131
- OPSUMIT$131
- Prolastin-C Liquid$116
- BREZTRI$104
- BEVESPI AEROSPHERE$104
- FASENRA$104
How this compares
$8,101 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 131 | $1,689,760 |
| ActharCorticotropin | 14 | $771,105 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 612 | $558,165 |
| OpsumitMacitentan | 38 | $461,994 |
| AdempasRiociguat | 33 | $407,934 |
| Orenitram ErTreprostinil Diolamine | 74 | $294,073 |
| Aralast NpAlpha-1-Proteinase Inhibitor | 13 | $177,711 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 183 | $167,002 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 12 | $114,459 |
| Pirfenidone | 52 | $98,478 |
| Spiriva RespimatTiotropium Bromide | 112 | $95,693 |
| Dupixent PenDupilumab | 21 | $82,884 |
| Breo ElliptaFluticasone/Vilanterol | 144 | $75,866 |
| TezspireTezepelumab-Ekko | 16 | $67,085 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 16 | $62,492 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $568 | $1,843,057325 claims |
| Mallinckrodt Hospital Products Inc.Acthar | $582 | $771,10514 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $1,056 | $682,370832 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $424 | $461,99438 claims |
| BayerAdempas | $16 | $407,93433 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort, Bevespi Aerosphere | $1,350 | $272,188291 claims |
| Grifols USA, LLCProlastin C, Gamunex-C | $850 | $146,18925 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.
Other family in Dallas
- David WeirDallas$959K
- Sie ThomasDallas$197K
- Hayley McKessonDallas$165K
- Marcia HarrisDallas$156K
- Miles HortonDallas$72K
- Richard OrnbergDallas$56K
- Ifeoma OkekeDallas$48K
- Natasha SimmonsDallas$38K
- Lashonda CraneHouston$3.4M
- Luba YammineHouston$479K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.